GLPwatch

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice

NCT05230589 · Completed

Last updated 2026-05-28

This study is testing how an oral medication called semaglutide affects blood sugar levels in adults with type 2 diabetes in Saudi Arabia as part of routine medical care.

Status Completed The study has finished.
Type Observational
Participants 194 people
Who can join Ages 18+ · all sexes
Timeline Started 2022-04 · est. completion 2023-03
Where 2 sites · Saudi Arabia

What this study is testing ClinicalTrials.gov NCT05230589 ↗

Description as written by the study sponsor.

The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.

Treatments tested

Main thing measuredChange in Glycated haemoglobin (HbA1c )
SponsorNovo Nordisk A/S
Conditions studiedDiabetes Mellitus, Type 2
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05230589 ↗